Corporate and Program Strategy

Before diving into a specific regulatory strategy, there are often corporate strategy questions to consider and answer:

  • What are the prospects of a pathway or class of therapeutics in light of the competitive landscape?
  • Should the biggest markets be pursued right off the bat? Or are there niche areas that might require less time, cost less, and increase the odds of a clear quick ‘win’ first?
  • Should the quickest route to regulatory clearance or approval be taken for a device, or is there a combination drug-device product strategy that could enable the company to access a drug pricing premium over device pricing?
  • What should the company pursue for the first target indication, in light of scientific, medical, regulatory and commercial considerations?
  •  
 

Our experts can help you think through such strategic questions, which could be some of the most consequential decisions you will make for fundraising, partnering and commercialization.

  • Target Product Profile
  • Program Prioritization and Portfolio Planning/Management
  • Competitive Landscape, Commercial Assessment and Valuation
  • Development Plan, Timeline and Budget
  • Commercial, Partnering and Payer Considerations
  • Fundraising